Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Cynthia L. Gong
Daratumumab vs. Pomalidomide for the Treatment of Relapsed/Refractory Multiple Myeloma: A Cost‐effectiveness Analysis
American Journal of Hematology
Hematology
United States Valuation of EQ-5D-5L Health States Using an International Protocol
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Related publications
Cost-Effectiveness of Pomalidomide, Carfilzomib, and Daratumumab for the Treatment of Patients With Heavily Pretreated Relapsed–refractory Multiple Myeloma in the United States
Clinical Therapeutics
Pharmacology
Bendamustine, Pomalidomide, and Dexamethasone for Relapsed and/or Refractory Multiple Myeloma
Blood Cancer Journal
Oncology
Hematology
Cost-Effectiveness Analysis of Daratumumab, Lenalidomide, and Dexamethasone (DRD) and Daratumumab, Bortezomib, and Dexamethasone (DVD) Versus Standard of Care in Relapsed or Refractory Multiple Myeloma (RRMM)
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Carfilzomib for Relapsed or Refractory Multiple Myeloma
The Lancet Oncology
Oncology
Orphan Designation: Pomalidomide, Treatment of Multiple Myeloma
Case Medical Research
Results of an Early Access Treatment Protocol of Daratumumab in United States Patients With Relapsed or Refractory Multiple Myeloma
Cancer
Cancer Research
Oncology
Daratumumab, Bortezomib and Dexamethasone (Dvd) vs Bortezomib and Dexamethasone (Vd) in Relapsed or Refractory Multiple Myeloma (Rrmm): Efficacy and Safety Update (Castor)
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Pcn173 - Cost-Effectiveness of New Triplet Combinations With Lenalidomide and Dexamethasone for Patients With Relapsed or Refractory Multiple Myeloma
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Psy63 - Cost by Outcomes Analysis of Novel Triple-Combination Therapies for Relapsed/Refractory Multiple Myeloma in Brazil
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
